Gene editing is the insertion, deletion or replacement of DNA at a specific site in the genome of living organism. Gene editing is a type of genetic engineering technique and is also called as genome editing. Gene editing can be accomplished by using engineered nucleases also known as molecular scissors. From the last few years, gene editing has been developed for wide range of experimental systems ranging from plants to animals and clinical applications. Gene editing method holds a promising future scope in becoming the standard experimental strategy in the field of genetic research. Gene editing can be done by using engineered nucleases such as ZFNs (zinc finger nucleases) or TALENs (transcription activator-like effector-based nucleases), CRISPR-Cas system (Clustered regularly interspaced short palindromic repeats), or with viral systems such as rAAV (recombinant adeno-associated virus). The gene editing companies classify gene editing in two categories namely the loss of function in which functional forms of the gene are taken off and the other is gain of function in which mutant active forms of the gene are introduced into the system. Gene editing provides an opportunity to perform same types of loss and gain of function experiments and manipulate genes of interest at the endogenous level.
A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/13459
Gene editing with engineered nucleases is anticipated to contribute significantly to the global life sciences industry. Gene editing provides application from studying gene functions in plants and animals to gene therapy in humans. Gene editing has more efficiency than many other methods in reverse genetics. Increased development of genetic engineering and increased funding in the field of gene editing is anticipated to drive the growth of the global gene editing market. Translating gene editing technologies to the clinic faces major challenges, primarily in terms of the safety and efficacy of these treatments. Gene editing is still not highly efficient and in many cases only less than half of the treated populations obtain the required changes. The factors such as unavailability of gene-editing based therapeutics in the global gene editing market can limit the growth of the global gene editing market during the forecast period.
The global Gene editing Market is segmented on the basis of applications, technology, products, end users and geography.
During the forecast period, production of efficient antivirals and various class of drugs on the basis of advanced gene editing technology is a major trend. The current technology in gene editing includes ZFN, TALEN, CRISPR, antisense, and other technologies. In coming years CRISPR is anticipated to be the most significant cancer treatment gene editing technology. The CRISPR technique is easy to use, affordable and works with high throughput and multi-gene experiments. That could be the reason the CRISPR is expected to grow with high growth rate in comparison with other techniques through 2024. Comparatively other techniques like ZFN, TALEN are still in dormancy and are expected to register steady growth rates during the forecast period.
The global Gene editing market is segmented into North America, Asia Pacific, Latin America, Europe, and Middle East & Africa (MEA). North America dominated the global genome editing market with the largest share in terms of value due to the factors such as increasing awareness of technology, presence of prominent key players, and early adoption of latest gene editing related treatment alternatives. Asia Pacific market is expected to grow steadily owing to slow adoption rate of latest gene technologies and fluctuating or unorganized regulatory environment, etc. But, the increasing government funding for research is expected to drive the Asia Pacific market growth through 2024.
Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/13459
Some of the global players in Gene editing market are such as Editas Medicine, Crispr Therapeutics, Intellia Therapeutics, Parker Institute, Cellectis, Thermo Fisher Scientific, Merck, Sangamo Biosciences and others. Out of global players, the Parker Institute has first Crispr-Cas9 human trial in pipeline & Merck has introduced gene editing technology to modify CHO cell lines resistant to minute virus of mice (MVM).
Persistence Market Research Pvt. Ltd
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353